溴尿嘧啶
医学
放射治疗
肿瘤科
放射性武器
阶段(地层学)
癌症
内科学
癌
化疗
免疫染色
外科
组蛋白
免疫组织化学
基因
生物
古生物学
生物化学
作者
Lauriane Lemelle,Antoine Moya‐Plana,Benoît Dumont,Brice Fresneau,Anne Laprie,L. Claude,Sophie Deneuve,Camille Cordero,Gaëlle Pierron,V. Couloigner,Sophie Bernard,Liesbeth Cardoen,Hervé J. Brisse,Nina Jehanno,Lucy Métayer,Paul Fréneaux,Sylvie Helfré,Frederic J. Kolb,Juliette Thariat,Yves Réguerre
标识
DOI:10.1016/j.bulcan.2022.01.015
摘要
NUT carcinoma (NC), defined by the presence of the NUTM1 rearrangement, is an aggressive tumour associated with poor prognosis. This rare cancer is underdiagnosed and difficult to treat.The primary objective of this review is to describe the clinical, radiological and laboratory features of NC in young patients. The secondary objective is to propose a consensual strategy for the French very Rare Tumour group (FRACTURE group).NUT-specific antibody immunostaining in cases of undifferentiated or poorly differentiated carcinoma may demonstrate the specific NUT gene rearrangement. NCs are frequently advanced stage at diagnosis and the outcome remains poor despite a global strategy that generally includes conventional combination chemotherapy with wide local therapy (surgery, radiotherapy). Chemosensitivity is frequently only transient.Recent data have shown that new targeted drugs (histone deacetylase and bromodomain and extra-terminal protein inhibitors) are promising, but their role has yet to be evaluated in NC. Centralized data review is necessary to improve our knowledge of paediatric NC. We propose a multimodal strategy based on published data and their personal experience.
科研通智能强力驱动
Strongly Powered by AbleSci AI